A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

NCT ID: NCT01113957

Last Updated: 2018-06-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 168 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2013-06-30

Brief Summary

The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian cancer.

Detailed Description

Safety assessments and tolerability will be assessed through electrocardiograms (ECG). clinical laboratory tests, vital signs, Adverse Event assessments, and physical exams. Baseline radiographic tumor assessments, including CT scans of the chest, abdomen and pelvis will be obtained. Radiologic assessments and CA-125 measurements will also be performed every 8 weeks during dosing and following completion of dosing until disease progression. Study visits will be conducted weekly for the first 2 cycles and on Day 1 of each subsequent cycle, at the Final Visit and 30 day Follow-up Visit. Study visits will include physical examination, complete blood count (CBC) and chemistries. A urinalysis tests will be performed at Screening and Final Visit. An ECG will be performed at Screening, Cycle 1 Day 1 and at the Final Study Visit. A left ventricular ejection fraction (LVEF) will be measured by Echocardiogram or Multiple Gated Acquisition (MUGA) scan on all subjects at Screening. Subjects randomized to the PLD arm will have an echocardiogram or MUGA performed at the Final Study Visit and at the discretion of the Investigator throughout the study. Adverse events will be assessed at every visit.

Conditions

Ovarian Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

ABT-888 in combination with temozolomide

Group Type: EXPERIMENTAL

ABT-888

Intervention Type: DRUG

Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally

temozolomide

Intervention Type: DRUG

Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888

Arm B

pegylated liposomal doxorubicin alone

Group Type: ACTIVE_COMPARATOR

pegylated liposomal doxorubicin

Intervention Type: DRUG

Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.

Interventions

ABT-888

Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally

Intervention Type: DRUG

pegylated liposomal doxorubicin

Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.

Intervention Type: DRUG

temozolomide

Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888

Intervention Type: DRUG

Other Intervention Names

ABT-888, veliparib; doxil/caelyx; temozolomide, temodar/temodal

Eligibility Criteria

Inclusion Criteria

• Subject must have histologically (or cytologically) confirmed recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer.
• Subjects must have had at least 1 platinum containing chemotherapy regimen and no more than a total of 3 DNA damaging or cytotoxic regimens in the last 5 years. Less than a full dose of a DNA damaging agent, possibly due to reasons such as toxicity or documented allergic reaction are allowed. Previous treatments with biologics (including catumaxomab, tigatuzumab, abagovomab, and bevacizumab), vaccines, immunostimulants, hormonal agents, and signal transduction inhibitors (e.g., pazopanib, sorafenib, sunitinib, temsirolimus) are allowed and are not counted towards the limit of 3.
• Subjects who are resistant to platinum-based therapy; or sensitive to but are unable to tolerate platinum-based therapy (i.e., deemed toxic or have a documented platinum allergy). Subjects must have at least a > 3 month treatment free interval from the last dose of platinum based therapy.
• Subject must be eligible for PLD treatment.
• Subject has either:

• Measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 OR
• Non-measurable disease with an elevation of serum CA-125 level by Gynecologic Cancer Intergroup (GCIG) criteria (baseline sample that is at least twice the upper limit of normal and within 2 weeks prior to starting treatment).
• Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.
• Subject must have adequate hematologic, renal and hepatic function as follows:

• Bone Marrow: Absolute neutrophil count (ANC ≥ 1,500/mm3 (1.5 x 109/L); Platelets ≥ 100,000/mm3 (100 x 109/L); Hemoglobin ≥ 9.5 g/dL (1.4 mmol/L);
• Renal function: Serum creatinine ≤ 1.5 x upper normal limit of institution's normal range OR creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal;
• Hepatic function: Aspartate aminotransferase (AST) and/or alanine transaminase (ALT) ≤ 2.5 x the upper normal limit of institution's normal range. For subjects with liver metastases, AST and/or ALT < 5 x the upper normal limit of institution's normal range; Bilirubin ≤ 1.5 x the upper normal limit of institution's normal range;
• Partial thromboplastin time (PTT) must be ≤ 1.5 x the upper normal limit of institution's normal range and international normalized ratio (INR) < 1.5. Subjects on anticoagulant (such as Coumadin) are allowed on study and will have PTT and INR as determined by the Investigator
• Women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and for 90 days following completion of therapy. Women of childbearing potential must have a negative serum pregnancy test within 21 days prior to initiation of treatment and a negative urine pregnancy test on Cycle 1 Day 1. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

Exclusion Criteria

• Subject has previously received a poly-ADP-ribose)-polymerase (PARP) inhibitor except a single dose from Cancer Therapy Evaluation Program (CTEP) Phase 0 (A06-161) study.
• Subjects who have a history of hypersensitivity reactions to a conventional formulation of doxorubicin hydrocloride (HCL) or the components of PLD.
• The subject has received an anticancer agents or an investigational agent within 28 days prior to study drug administration. Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.
• Subject has undergone major surgery within the previous 28 days prior to study drug administration.
• Subjects with prior radiotherapy to any portion of the abdominal cavity and pelvis, unless for the treatment of ovarian, primary peritoneal or fallopian tube cancer. Subject must have completed radiation at least 28 days prior to study drug administration and have measurable disease outside the radiation field or documented progression of lesions within a previously radiated field.
• Subjects with a known history of brain metastases.
• Clinically significant and uncontrolled major medical condition(s) including but not limited to:

• Active uncontrolled infection
• Symptomatic congestive heart failure
• Unstable angina pectoris or cardiac arrhythmia
• Psychiatric illness/social situation that would limit compliance with study requirements
• Any medical condition, which is in the opinion of the Study Investigator, places the subject at an unacceptably high risk for toxicities
• Subject is pregnant or lactating.
• Subjects who requires parenteral nutrition, or tube feeding or has evidence of partial bowel obstruction or perforation.
• The subject has had another active malignancy within the past five years except for any cancer in situ considered cured or non-melanoma carcinoma of the skin. Questions regarding the inclusion of individual subject should be directed to the Abbott Medical Monitor.
• Subject has previously received a poly-ADP-ribose)-polymerase (PARP) inhibitor except a single dose from Cancer Therapy Evaluation Program (CTEP) Phase 0 (A06-161) study. - Subjects who have a history of hypersensitivity reactions to a conventional formulation of doxorubicin hydrocloride (HCL) or the components of PLD.
• The subject has received an anticancer agents or an investigational agent within 28 days prior to study drug administration. Subjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to previous anticancer treatment are excluded.
• Subject has undergone major surgery within the previous 28 days prior to study drug administration.
• Subjects with prior radiotherapy to any portion of the abdominal cavity and pelvis, unless for the treatment of ovarian, primary peritoneal or fallopian tube cancer. Subject must have completed radiation at least 28 days prior to study drug administration and have measurable disease outside the radiation field or documented progression of lesions within a previously radiated field.
• Subjects with a known history of brain metastases.
• Clinically significant and uncontrolled major medical condition(s) including but not limited to:

• Active uncontrolled infection
• Symptomatic congestive heart failure
• Unstable angina pectoris or cardiac arrhythmia
• Psychiatric illness/social situation that would limit compliance with study requirements
• Any medical condition, which is in the opinion of the Study Investigator, places the subject at an unacceptably high risk for toxicities
• Subject is pregnant or lactating.
• Subjects who requires parenteral nutrition, or tube feeding or has evidence of partial bowel obstruction or perforation.
• The subject has had another active malignancy within the past five years except for any cancer in situ considered cured or non-melanoma carcinoma of the skin. Questions regarding the inclusion of individual subject should be directed to the Abbott Medical Monitor.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 99 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

AbbVie (prior sponsor, Abbott)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark D McKee, MD

Role: STUDY_DIRECTOR

AbbVie

Locations

Site Reference ID/Investigator# 25028

Duarte, California, United States

Site Reference ID/Investigator# 25024

Encino, California, United States

Site Reference ID/Investigator# 25034

Los Angeles, California, United States

Site Reference ID/Investigator# 25037

Newport Beach, California, United States

Site Reference ID/Investigator# 25030

Chicago, Illinois, United States

Site Reference ID/Investigator# 27837

Park Ridge, Illinois, United States

Site Reference ID/Investigator# 25039

Peoria, Illinois, United States

Site Reference ID/Investigator# 25038

Albuquerque, New Mexico, United States

Site Reference ID/Investigator# 25023

New York, New York, United States

Site Reference ID/Investigator# 25041

Chapel Hill, North Carolina, United States

Site Reference ID/Investigator# 25029

Hilliard, Ohio, United States

Site Reference ID/Investigator# 25543

Oklahoma City, Oklahoma, United States

Site Reference ID/Investigator# 25036

Philadelphia, Pennsylvania, United States

Site Reference ID/Investigator# 25042

Pittsburgh, Pennsylvania, United States

Site Reference ID/Investigator# 25027

Houston, Texas, United States

Site Reference ID/Investigator# 25128

Adelaide, , Australia

Site Reference ID/Investigator# 25130

Bedford Park, , Australia

Site Reference ID/Investigator# 25131

East Melbourne, , Australia

Site Reference ID/Investigator# 25133

Nedlands, , Australia

Site Reference ID/Investigator# 25132

Randwick, , Australia

Site Reference ID/Investigator# 25129

Westmead, , Australia

Site Reference ID/Investigator# 25166

Edmonton, , Canada

Site Reference ID/Investigator# 25162

Kelowna, , Canada

Site Reference ID/Investigator# 25165

Laval, , Canada

Site Reference ID/Investigator# 25135

Budapest, , Hungary

Site Reference ID/Investigator# 25138

Haifa, , Israel

Site Reference ID/Investigator# 25139

Tel Aviv, , Israel

Site Reference ID/Investigator# 25141

Tel Litwinsky, , Israel

Site Reference ID/Investigator# 25402

Auckland, , New Zealand

Site Reference ID/Investigator# 25145

Warsaw, , Poland

Site Reference ID/Investigator# 25149

Northwood, , United Kingdom

Site Reference ID/Investigator# 25154

Oxford, , United Kingdom

Countries

United States; Australia; Canada; Hungary; Israel; New Zealand; Poland; United Kingdom

References

Elit L, Hirte H. Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options. Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.

Reference Type: BACKGROUND

PMID: 23459506 (View on PubMed)

Other Identifiers

2009-015082-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M10-757

Identifier Type: -

Identifier Source: org_study_id